It may seem, at least to those of us who have been alive long enough to witness any of the advances in semiconductor technology, that computer power has been improving at breakneck speed. A quantum computer, however - a theoretical type of computer that utilizes the states of atoms to store information instead of magnetic fields - may make our current conception of computing power completely obsolete. And now, new research into the storage and retrieval of quantum information has brought quantum computing one step closer to reality.

Since the 80’s, as the awareness of HIV has increased exponentially, scientists have struggled for a vaccine to quell the rising number of AIDS-related deaths occurring each year. According to an AIDS epidemic update released in December of 2006  by the Joint United Nations Program on HIV/AIDS (UNIADS) and the World Health Organization (WHO), there were 39.5 million people worldwide living with HIV. That includes the 4.3 million newly infected individuals that year alone, and not including the 2.9 million deaths from AIDS in 2006.

GENEVA, December 8 /PRNewswire/ -- Emailvision, the first European market and technology leader in on-demand software for e-mail marketing automation, is pleased to announce the official creation of its swiss subsidiary in Geneva.

Emailvision has organized a client cocktail on Thursday December 11th at 5pm at FloorTwo (lounge bar of Kempinski Hotel) with Nick Heys - CEO Founder, Guy Porre - CCO General Manager and Herve Bloch -Managing Director Emailvision Switzerland.

From his nomination to Country Manager Position in April 2008, Herve Bloch recruited sales and production teams for Geneva as well as for our Zurich office. Those teams will manage Switzerland operations and also East European Russian activities.

GÜTERSLOH, Germany, December 8 /PRNewswire/ -- LYCOS Europe introduces STRATO a strong European Webhosting provider, as its exclusive partner for LYCOS Webhosting customers who based on the current situation would like to re-orientate themselves.

STRATO and LYCOS are currently focusing on the transferring of domains which will guarantee in making the transition as easy as possible.

In addition STRATO are offering free of charge a Hotline, Online-Chat and Call-back service for any queries that might arise.

More information relating this partnership will be released mid December. The LYCOS Webhosting branch will still be operating during the first quarter of 2009.

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Symposium (SABCS) and Agendia will support, with an unrestricted grant, the New Frontiers in Individualized Breast Cancer Therapy symposium. The San Antonio Breast Cancer Symposium, one of the premiere conferences in breast cancer research worldwide, takes place December 10th-14th, 2008.

REYKJAVIK, Iceland, December 8 /PRNewswire/ --

deCODE genetics (Nasdaq: DCGN) today announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated with increased fasting glucose levels and risk of type 2 diabetes (T2D). deCODE will employ its CLIA-registered genotyping laboratory and existing testing platform to swiftly integrate the finding into its deCODEme(TM) personal genome scan, and to assess the addition of this new variant to the company's deCODE T2(TM) reference laboratory test for assessing individual risk of type 2 diabetes.

ZURICH, Switzerland, December 8 /PRNewswire/ --

- Breakthrough Home Use Study Finalised

- Board of Directors Reinforced

Solianis has just finalised a test series in which patients with diabetes have worn the first configuration of the multisensor system for non-invasive Continuous Glucose Monitoring at home and at work. Results show that the system tracks glucose in these settings and that it is sensitive to hyper- and hypoglycemic glucose excursions.

SAN JOSE, California, December 8 /PRNewswire/ --

Super Micro Computer, Inc. (Nasdaq: SMCI), a leader in application-optimized, high performance server solutions, today announced that the channel has ranked Supermicro as the number one x86 server vendor over HP, IBM, Dell, Sun, Apple and Gateway. As published in the November 24th issue of CRN (Channel Reseller News), the 2008 Channel Affinity Index, which is based on the result of 8,000 survey responses conducted with solutions providers, ranks Supermicro as the top x86 server vendor.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081208/AQM062)

PORTO, Portugal, December 8 /PRNewswire/ --

- Data Highlight The Efficacy, Safety and Significant Improvement in Quality of Life and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine Acetate)

Positive data from three phase III studies presented today at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM)(1) (eslicarbazepine acetate), a novel once-daily anti-epileptic agent, significantly reduced the frequency of partial seizures and has the potential to significantly improve quality of life and depressive symptoms in patients with partial refractory epilepsy, in combination with other anti-epileptic agents.(2),(3),(4)

Zebinix(TM) is one of the proposed EU trade names for eslicarbazepine acetate.

AMSTERDAM, December 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc(TM) Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc(TM) is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

This is an important strategic milestone in the development of Reviroc(TM) and we are very pleased with the orphan drug designations received from the FDA, says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.